Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Breast cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- 10 Dec 2018 Planned End Date changed from 1 Jan 2021 to 31 Dec 2022.
- 14 Nov 2017 Status changed from not yet recruiting to recruiting.
- 24 May 2017 New trial record